Greenwich LifeSciences, Inc.
GLSI
$11.67
-$0.26-2.18%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 538.00K | 681.20K | 1.93M | 437.00K | 353.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.05M | 3.28M | 8.08M | 2.73M | 2.66M |
| Operating Income | -4.05M | -3.28M | -8.08M | -2.73M | -2.66M |
| Income Before Tax | -4.03M | -3.26M | -8.04M | -2.67M | -2.61M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.03M | -3.26M | -8.04M | -2.67M | -2.61M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.03M | -3.26M | -8.04M | -2.67M | -2.61M |
| EBIT | -4.05M | -3.28M | -8.08M | -2.73M | -2.66M |
| EBITDA | -4.05M | -3.28M | -8.08M | -2.73M | -2.66M |
| EPS Basic | -0.30 | -0.25 | -0.61 | -0.20 | -0.20 |
| Normalized Basic EPS | -0.19 | -0.15 | -0.38 | -0.13 | -0.13 |
| EPS Diluted | -0.30 | -0.25 | -0.61 | -0.20 | -0.20 |
| Normalized Diluted EPS | -0.19 | -0.15 | -0.38 | -0.13 | -0.13 |
| Average Basic Shares Outstanding | 13.37M | 13.17M | 13.15M | 13.14M | 12.91M |
| Average Diluted Shares Outstanding | 13.37M | 13.17M | 13.15M | 13.14M | 12.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |